Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LM-101 (LipoMedics Inc.)
- Development stage
- Preclinical
- Lead developer
- LipoMedics
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
LM-101 is an injectable phospholipid-bound nanoparticle formulation of paclitaxel developed by LipoMedics. Described as a "Third Generation Abraxane," it utilizes a phospholipid-lysophospholipid platform to deliver paclitaxel, a microtubule stabilizer that binds to tubulin to inhibit cell division. The formulation is designed to retain the plasma dissolution characteristics of Abraxane while improving stability compared to second-generation formulations like Genexol-PM. It is being developed for the treatment of various solid tumors, including metastatic breast cancer, ovarian cancer, pancreatic cancer, and non-small cell lung cancer (NSCLC).
- Other names
- Next Generation NP-PaclitaxelNanoparticle PaclitaxelNP-Paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on LM-101 (LipoMedics Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LM-101 (LipoMedics Inc.).